NASDAQ$CODX

Co-Diagnostics Inc · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Reported robust sales of COVID-19 tests and generated net profit through middle of second quarter.

Co-Diagnostics reported strong Q1 2020 results driven by robust sales of COVID-19 tests and achieved net profitability through the middle of the second quarter of 2020.

  • Increased production capacity to meet growing demand for tests.
  • Positioned to continue making an important contribution in meeting the enormous demand for tests around the world.
  • Value proposition of accurate, high-throughput, and cost-effective tests continues to resonate with customers globally.
  • Generated net profit through middle of second quarter

Headline financials

Total Revenue

$1.55M

Previous: $3.4K+45444.9%
EPS (adj)

-$0.05

Previous: -$0.09+44.4%
Capital Expenditures

-$100K

No prior period
Free Cash Flow

-$1.17M

Previous: -$1.37M+14.8%
Net Income

-$1.07M

Previous: -$1.37M+22.2%
Operating Income

-$1.08M

Previous: -$1.25M+13.8%
Gross Profit

$1.07M

Previous: $2.95K+36086.8%
Cash & Equivalents

$17.4M

No prior period
Total Assets

$20.5M

No prior period
Stock-Based Comp

$433K

No prior period

Revenue & EPS history

Co-Diagnostics · Revenue · Quarterly

$1.55M

Q1 2020+45,444.9%vs Q1 2019
Beat estimate in 5 of 9 quarters(56%)
ActualEstimate

Revenue by segment

Co-Diagnostics · $146K total across 1 segment · Q1 2026

  • Product
    $146K

Forward guidance

The press release contains forward-looking statements regarding the use of funding proceeds, expansion of product distribution, acceleration of initiatives in liquid biopsy and SNP detection, use of the Company’s liquid biopsy tests by laboratories, capital resources and runway needed to advance the Company’s products and markets, increased sales in the near-term, flexibility in managing the Company’s balance sheet, anticipation of business expansion, and benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages.

Tailwinds

  • Use of funding proceeds
  • Expansion of product distribution
  • Acceleration of initiatives in liquid biopsy and SNP detection
  • Use of the Company’s liquid biopsy tests by laboratories
  • Benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages.

Headwinds

  • Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.
  • Actual results may differ materially from those contemplated or anticipated by such forward-looking statements.
  • Readers of this press release are cautioned not to place undue reliance on any forward-looking statements.
  • The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

-5.3%

Avg return

Earnings day

-3.9%

Avg return

5 days after

+0.6%

Avg return

30 days after

34%

12 / 35 earnings

Positive

+21.0%

Q1 2022

Best reaction

-32.3%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.6%+24.4%+169.2%
Q3 2025-11.4%-8.1%-8.3%
Q2 2025+11.7%+6.4%+28.7%
Q1 2025-2.4%-2.8%-15.5%
Q4 2024-18.3%-8.7%-10.7%
Q3 2024-5.8%-3.3%-29.7%
Q2 2024+4.7%+9.3%+25.2%
Q1 2024-9.0%-8.2%+10.7%
Q4 2023-9.3%-6.8%+1.7%
Q3 2023-7.3%+9.8%-0.8%
Q2 2023-10.8%-6.9%-5.4%
Q1 2023+0.8%+4.9%-20.9%
Q4 2022-14.8%-34.4%-46.4%
Q3 2022+8.6%+9.7%-17.4%
Q2 2022-32.3%-37.9%-50.6%
Q1 2022+21.0%+33.8%+35.1%
Q4 2021-8.3%+4.0%-24.4%
Q3 2021+7.8%+13.1%-2.3%
Q2 2021+11.0%+15.6%+10.8%
Q1 2021+15.7%+20.4%+20.8%
Q4 2020-21.8%-31.1%-27.8%
Q3 2020-20.6%-26.0%-28.8%
Q2 2020-16.8%-21.2%-29.9%
Q1 2020-27.1%-19.5%-33.5%
Q4 2019-16.7%-10.4%+35.2%
Q3 2019-4.3%-3.9%+7.1%
Q2 2019-11.1%-8.1%-13.5%
Q1 2019-14.2%-20.3%-25.7%
Q4 2018+5.6%+0.0%-8.2%
Q3 2018+2.3%-9.3%-13.1%
Q2 2018-1.4%-4.5%-10.8%
Q1 2018-8.1%-7.0%+129.7%
Q4 2017-5.9%-11.3%-14.9%
Q3 2017-3.2%-6.8%-43.4%
Q2 2017+3.2%+9.4%+29.0%
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016
Q4 2015

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro